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Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a variety of patient populations,
with heterogeneous results regarding benefit and safety, specifically with regard to cardiovascular and non-cardiovas-
cular mortality. We performed a meta-analysis of randomized trials comparing more than a year of DAPT with aspirin
alone in high-risk patients with a history of prior myocardial infarction (MI).
Methods
and results
A total of 33 435 patients were followed over a mean 31 months among one trial of patients with prior MI (63.3% of total)
and five trials with a subgroup of patients that presented with, or had a history of, a prior MI (36.7% of total). Extended
DAPT decreased the risk of major adverse cardiovascular events compared with aspirin alone (6.4 vs. 7.5%; risk ratio, RR
0.78, 95% confidence intervals, CI, 0.67–0.90; P ¼ 0.001) and reduced cardiovascular death (2.3 vs. 2.6%; RR 0.85, 95% CI
0.74–0.98; P ¼ 0.03), with no increase in non-cardiovascular death (RR 1.03, 95% CI 0.86–1.23; P ¼ 0.76). The resultant
effect on all-cause mortality was an RR of 0.92 (95% CI 0.83–1.03; P ¼ 0.13). Extended DAPT also reduced MI (RR 0.70,
95% CI 0.55–0.88; P ¼ 0.003), stroke (RR 0.81, 95% CI 0.68–0.97; P ¼ 0.02), and stent thrombosis (RR 0.50, 95% CI
0.28–0.89; P ¼ 0.02). There was an increased risk of major bleeding (1.85 vs. 1.09%; RR 1.73, 95% CI 1.19–2.50;
P ¼ 0.004) but not fatal bleeding (0.14 vs. 0.17%; RR 0.91, 95% CI 0.53–1.58; P ¼ 0.75).
Conclusion Compared with aspirin alone, DAPT beyond 1 year among stabilized high-risk patients with prior MI decreases ischae-
mic events, including significant reductions in the individual endpoints of cardiovascular death, recurrent MI, and stroke.
Dual antiplatelet therapy beyond 1 year increases major bleeding, but not fatal bleeding or non-cardiovascular death.
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Introduction
Patients with myocardial infarction (MI) have heightened platelet
activation and aggregation resulting in atherothrombosis following
the rupture or fissuring of an unstable atherosclerotic plaque com-
pared with patients with stable ischaemic heart disease (SIHD).1 – 3
A higher predisposition to atherothrombosis may persist for years
following an MI,3 – 6 and SIHD patients with a history of an MI are
at high risk for major adverse cardiovascular events (MACE).7 – 9 As
such, following MI, patients may have a persistent pathobiology
that predisposes them to benefit more from therapies that
intensely inhibit platelet activation and aggregation than patients
following percutaneous coronary intervention (PCI) for stable
ischaemia.10
However, dual antiplatelet therapy (DAPT) with a platelet adeno-
sine diphosphate (ADP) antagonist in addition to aspirin is strongly
recommended for only up to 1 year for reduction of cardiovascular
events in patients with a prior MI, with a weak recommendation to
continue thereafter in patients who underwent PCI based on expert
consensus.11 – 15 In the absence of definitive longer-term data,
DAPT is often stopped after completion of 1 year of treatment in
half of all patients.16 Recently, two large randomized controlled
trials (RCTs) demonstrated that extended duration of DAPT signifi-
cantly reduced atherothrombotic events in patients 1 year or more
following an MI17 or a PCI18 at the expense of higher bleeding and, in
the case of the PCI trial,18 potentially a higher risk of death from
non-cardiovascular causes. Given these findings, and the heterogen-
eity in results of other trials testing extended duration DAPT, we
sought to better understand the cardiovascular benefits and risks
of DAPT beyond 1 year for secondary prevention in high-risk pa-
tients with a prior MI.
Methods
Study design
This systematic review and meta-analysis was conducted in accordance
with the recommendations of the Cochrane Collaboration and the Pre-
ferred Reporting Items for Systematic reviews and Meta-Analyses guide-
lines.19 The previously published study protocol is available at the
PROSPERO registry (www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42015019657) and Supplementary material online,
Appendix.
Eligibility criteria and trial selection
We considered prospective RCTs of secondary prevention eligible
for inclusion if they followed patients beyond 1 year that either pre-
sented with or had a history of a prior MI and were randomized to a
strategy of extended duration (beyond 12 months) DAPT compared
with aspirin alone (with or without the use of a placebo for blinding).
Eligible RCTs were considered irrespective of language, blinding, and
publication status. We excluded observational studies. We excluded
trials of DAPT among patients presenting with MI who were followed
no longer than 12 months; if such trials followed patients longer, we
considered 1-year landmark results of MI patients randomized to
DAPT beyond 12 months as a sensitivity analysis. We also excluded
trials of patients with SIHD alone undergoing PCI and trials of oral anti-
coagulant therapies.
Search strategy and data extraction
We conducted a literature search of OVID Medline (1950 to 2 April
2015) and the Cochrane central register of controlled trials databases,
utilizing keyword search terms including: ‘antiplatelet’, ‘DAPT’, ‘thieno-
pyridine’, ‘secondary prevention’, ‘MI’, ‘acute coronary syndrome’,
‘major adverse cardiovascular events’, ‘death’, ‘mortality’, and ‘survival’
(see Supplementary material online, Search Strategy). We reviewed
Supplementary material online, Appendices and reference lists of eli-
gible papers, cardiovascular conference abstracts between 2014 and
2015, and clinicaltrials.gov, to ensure identification of relevant published
and unpublished studies. If published data were not available, we con-
tacted the study principal investigator (PI) for input to maximize contri-
bution to, and harmonize outcomes.
Baseline characteristics data and outcomes were abstracted for each
study from the published manuscripts, appendices, or unpublished data
by two investigators (J.A.U. and D.L.B.) independently. Baseline charac-
teristics included patient data and study design characteristics [year, clin-
ical setting (major inclusion and exclusion criteria) sample size,
randomized intervention and control, duration of difference in interven-
tion, duration of follow-up, blinding, and primary endpoint]. Results
were compared and any disagreements were resolved by consensus.
Quality assessment
Quality was graded based on documentation of trial conduct criteria
such as method of randomization, allocation concealment and blinding,
blinded outcome adjudication, extent of outcome reporting and ascer-
tainment, participant attrition and adherence metrics.20 Studies were
categorized as high quality if criteria were clearly described and ac-
counted for, low quality if any aspect of the first three criteria was un-
accounted for, or otherwise of uncertain risk of bias.
Outcomes
The primary endpoint for this analysis was the incidence of MACE,
which was defined as a composite of cardiovascular death, non-fatal
MI, and non-fatal stroke. Secondary endpoints included individual com-
ponents of the composite primary endpoint, all-cause death, non-
cardiovascular death, major bleeding events, and when relevant stent
thrombosis. All cardiovascular endpoints were adjudicated and defined
within the individual trials according to standard criteria. Major bleeding
events were considered according to standardized bleeding endpoint
definitions reported in each trial (see Supplementary material online, Ta-
ble S1 describes individual trial endpoint definitions).21
Statistical analysis
Data for patients that either presented with or had a history of a quali-
fying MI at baseline were extracted and descriptive characteristics were
summarized using means (standard deviation), medians (interquartile
range), or rates from each study weighted according to individual sample
sizes. We extracted the originally reported hazard ratios (HRs) and 95%
confidence intervals (CI) from each study when available and otherwise
calculated risk ratios (RRs) and 95% CI from the reported number of
events and patients at risk per treatment arm. Data from each trial
were considered as per the intention-to-treat principle with pooled
summary RR and 95% CI derived using a random effects meta-analysis
model with weighting based on inverse variance. If a particular endpoint
was not reported in a trial, and it could not be deduced from other out-
comes or provided by the study PI, it was excluded only from that spe-
cific endpoint’s pooled analysis. A correction factor of 0.5 was added to
values of a treatment arm when no events were observed for calculation
of the RR for an endpoint and its variance. We used the Cochran Q stat-
istic and the I2 measure to assess heterogeneity for treatment effects
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across trials, with an I2 . 75% considered representative of high hetero-
geneity. We performed sensitivity analyses including sequentially re-
moving studies from the pooled effect estimates and adding studies
with applicable 1-year landmark analyses. Heterogeneity among se-
lected subgroups was also explored according to age, sex, DAPT regi-
men, type of index myocardial event, time from the index MI, and in
patients with and without a history of PCI, diabetes, additional MI, stroke
or transient ischaemic attack (TIA), or chronic kidney disease. An inter-
action term representing each category was introduced into the model
for MACE and major bleeding to test for differences in treatment effect
between subgroups. Publication bias was evaluated by visual inspection
of funnel plots, without further statistical testing given these tests have
limited specificity and power when ,10 studies are analysed.22 Two-
sided P-values were calculated with ,0.05 considered significant for
all analyses. Statistical analyses were performed with Review Manager
version 5.3.5 (Nordic Cochrane Centre, Denmark) and Comprehensive
Meta-Analysis version 3.0 (Biostat Inc., Englewood, NJ, USA).
Role of the funding source
There was no funding source for this study. J.A.U. and D.L.B. had full ac-
cess to all the data in the study and had final responsibility for the deci-
sion to submit for publication. All included studies complied with the
Declaration of Helsinki and individual ethics committees approved the
research protocols and informed consent was obtained from subjects in
each respective trial.
Results
Among 1342 records screened, we identified 36 RCTs to review in
detail (see Supplementary material online, Results and Figure S1).
After exclusions, the remaining six trials met criteria for eligibility
in the primary meta-analysis.17,18,23 – 29 These trials, which com-
prised 33 435 participants randomized to a strategy of extended
DAPT (n ¼ 20 203) vs. aspirin alone (n ¼ 13 232), are summarized
in Table 1. One trial exclusively randomized patients with a history
of MI (n ¼ 21 162; 63.3% of the pooled population),17 one rando-
mized a subgroup of patients with prior MI (n ¼ 3846; 11.5%),23,24
while the remaining four trials randomized patients that recently
underwent PCI and included a subgroup whose indication was an
acute coronary syndrome (n ¼ 8427; 25.2%).18,25 – 29 Various ADP
antagonists were studied across the six trials as outlined in Table 1,
including clopidogrel, prasugrel, and ticagrelor.
At baseline, overall, the mean age of participants was 64.0 years,
mean weight was 81.4 kg, 7900 (23.6%) were women, 28 064
(83.9%) underwent or had a history of PCI, 9888 (29.6%) had dia-
betes, 5439 (18.6%) had chronic kidney disease, and 16 340
(48.9%) presented with or had a history of ST-elevation or
Q-wave MI (see Supplementary material online, Table S2). Enrolled
patients infrequently presented with unstable angina (n ¼ 2384;
7.1%), with a history of stroke/TIA (n ¼ 866; 2.6%), or with a history
of revascularization by coronary artery bypass grafting (n ¼ 2477;
7.4%). The mean duration of follow-up of 31 months and the
mean difference in the achieved duration of DAPT was 30 months
(range 17–36 months).
Quality metrics of trial conduct, participant attrition, and thera-
peutic adherence across trials are summarized (see Supplementary
material online, Table S3) and were reasonably comparable for trials
that varied in length of follow-up, timing of randomization, and type
of intervention. Three trials were double blind and placebo-
controlled,17,18,23,24,29 while three were unmasked open-label
trials with blinded endpoint adjudication and standard care as the
control.25– 28 Forgiving unblinded study designs, all trials were con-
sidered high quality. All trials reported or provided results for
MACE, CV death, MI, stroke, major bleeding, non-CV death, and
all-cause mortality (see Supplementary material online, Table S1).
Cardiovascular endpoints, cause of death, and major bleeding events
were defined in each trial according to standard diagnostic criteria
and were adjudicated by a blinded endpoints committee in each trial
allowing for comparisons across trials. Four of six trials provided
data for stent thrombosis.18,25– 29 Causes of major bleeding events
were also provided by all trials (see Supplementary material online,
Table S4).
Major adverse cardiovascular events
Among the six trials, the individual and pooled HR/RRs for the com-
posite primary endpoint of the 2273 MACE are provided in Figure 1.
Among the 20 203 participants with a prior MI treated with DAPT
beyond 1 year, 1286 (6.37%) patients developed a MACE compared
with 987 of 13 232 (7.46%) patients treated with aspirin alone [RR
0.78 (95% CI 0.67–0.90); P ¼ 0.001; Figure 1]. This risk reduction re-
presented an absolute risk difference (ARD) of 1.09% (95% CI
0.53–1.65) or a number needed to treat (NNT) of 91 (95% CI
61–189) to prevent one MACE over a mean 31 months of
follow-up.
Cardiovascular mortality
Extended DAPT for more than a year following an MI significantly
reduced cardiovascular death (which comprised 60% of all observed
deaths) (Figure 2), as 472 of 20 203 patients (2.3%) died from cardio-
vascular causes while treated with extended DAPT compared with
344 of 13 232 patients (2.6%) treated with aspirin alone [RR 0.85
(95% CI 0.74–0.98); P ¼ 0.03; ARD ¼ 0.26%; NNT ¼ 380; see Sup-
plementary material online, Figure S2].
Other individual cardiovascular endpoints
Extended DAPT also significantly reduced the risk of MI [RR 0.70
(95% CI 0.55–0.88); P ¼ 0.003; ARD ¼ 0.84%; NNT ¼ 120; see
Supplementary material online, Figure S3] and stroke [RR 0.81
(95% CI 0.68–0.97); P ¼ 0.02 ARD ¼ 0.31%; NNT ¼ 324; see Sup-
plementary material online, Figure S4]. Among trials that enrolled
only PCI-treated patients, definite or probable stent thrombosis
events were infrequent. Yet the risk of late stent thrombosis
more than a year following an MI was significantly reduced with ex-
tended DAPT [RR 0.50 (95% CI 0.28–0.89); P ¼ 0.02; ARD ¼
0.73%; NNT ¼ 137; see Supplementary material online, Figure S5].
Major bleeding events and safety
These results occurred in the context of an increased risk of major
bleeding events with extended DAPT [1.85 vs. 1.09%; RR 1.73 (95%
CI 1.19–2.50); P ¼ 0.004; ARD ¼ 0.76%; NNH ¼ 132; Figure 2 and
see Supplementary material online, Figure S6]. However, intracranial
haemorrhage (ICH) [0.41 vs. 0.31%; RR 1.34 (95% CI 0.89–2.02);
P ¼ 0.17] and fatal bleeding events [0.14 vs. 0.17%; RR 0.91 (95%
CI 0.53–1.58); P ¼ 0.75] were infrequent and were not significantly
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Table 1 Characteristics of included trials
Trial Population included in the
present study
N (% of total
trial
enrolment)
Time from MI/ACS
to randomization
(months)a
Study design and
time from
randomisation to
DAPT initiation or
continuation
(months)a
Difference in
duration of
DAPT
(months)a
Follow-up
(months)a
Intervention, N Control, N
Background of aspirin
CHARISMA MI
(2006)23,24
Patients ≥45 years of age with
documented CAD, CVD, or PAD,
or with multiple atherothrombotic
risk factors. The subgroup of
interest was patients with prior MI.
Excluded patients with an existing
indication for clopidogrel, including
a recent ACS, or at high risk of
bleeding, including long-term oral
anticoagulation or NSAID use
3846 (24.6) 23.6 (NR) DAPT initiation, 0 27.6 (NR) 27.6 (NR) Clopidogrel, 1903 Placebo, 1943
PRODIGY (2012)25,26 The subgroup of stabilized patients
≥18 years of age with prior ACS
treated with PCI. Excluded patients
with a bleeding diathesis, oral
anticoagulation, planned surgery,
active bleeding, or prior stroke in
the past 6 months
1465 (74.4) 1 (NR) DAPT continuation, 5
(NR)
18 (NR) 24 (NR) Clopidogrel, 732 No therapy 733
ARCTIC-Interruption
(2014)27
The subgroup of stabilized patients
≥18 years of age with prior ACS
treated with PCI who were free of
MACE and major bleeding at 12
months. Excluded patients at
physician’s discretion, those .15
months from prior randomization,
with aspirin resistance, chronic
anticoagulation treatment, bleeding
diathesis, bleeding GI ulcer, or
presentation with STEMI
323 (25.7) 12 (NR) DAPT continuation, 0 17 (15–18) 17 (15–18) Clopidogrel or
prasugrel, 156
No therapy, 167
DAPT (2014)18,29 The subgroup of stabilized patients
.18 years of age with prior MI
treated with PCI who were free of
MACE and major bleeding at 12
months. Excluded patients with a
bleeding diathesis, oral
anticoagulation, planned surgery,
and index PCI with concomitant
DES and BMS
3576 (30.7) 12 (NR) DAPT continuation, 0 18 (NR) 18 (NR) Clopidogrel or
prasugrel, 1805
Placebo, 1771
Continued
Long-term
dualantiplatelet
therapy
for
secondary
prevention
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Table 1 Continued
Trial Population included in the
present study
N (% of total
trial
enrolment)
Time from MI/ACS
to randomization
(months)a
Study design and
time from
randomisation to
DAPT initiation or
continuation
(months)a
Difference in
duration of
DAPT
(months)a
Follow-up
(months)a
Intervention, N Control, N
Background of aspirin
DES-LATE (2014)28 The subgroup of stabilized patients
≥18 years of age with prior ACS
treated with PCI who were free of
MACE and major bleeding at 12
months. Excluded patients with
contraindication to antiplatelet
drugs or an indication for long-term
clopidogrel
3063 (60.7) 13.3 (12.1–16.1) DAPT continuation, 0 36 (NR) 42.0 (24.7–
50.7)
Clopidogrel, 1512 No therapy,
1551
PEGASUS-TIMI 54
(2015)17
Patients ≥50 years of age with prior MI
1–3 years before enrolment with
one additional risk factor. Excluded
patients with planned DAPT or
anticoagulation, patients with a
bleeding diathesis or recent (,6
months) GI bleed, recent major
surgery (,1 month), and any prior
ischaemic or haemorrhagic stroke
21 162 (100) 20.4 (14.4–27.6) DAPT initiation, 0 33 (28–37) 33 (28–37) Ticagrelor 90 mg
b.i.d., 7050
60 mg b.i.d.,
7045
Placebo, 7067
Total 33 435 18 30 31 20 203 13 232
Trial No. of MACE events Control group
MACE rate
Control group major
bleeding rate
Control group
annualized MACE
rate
Control group
annualized
major
bleeding
rate
CHARISMA MI
(2006)23,24
287 8.3 2.0 3.6 0.87
PRODIGY (2012)25,26 132 9.4 0.8 4.7 0.4
ARCTIC-Interruption
(2014)27
7 2.4 0 1.7 0
DAPT (2014)18,29 167 6.3 0.8 4.2 0.53
DES-LATE (2014)28 122 4.3 2.0 1.2 0.57
PEGASUS-TIMI 54
(2015)17
1558 9.0 1.1 3.3 0.39
Total 2273 7.5 1.1
ACS, acute coronary syndrome; BMS, bare metal stent; CAD, coronary artery disease; CVD, cerebrovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; GI, gastrointestinal; MACE, major adverse cardiovascular events; MI,
myocardial infarction; NR, not reported; NSAID, non-steroidal anti-inflammatory drug; PAD, peripheral arterial disease; STEMI, ST-segment elevation MI; TIA, transient ischaemic attack.
aMean (standard deviation) or median (interquartile range).
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different between extended DAPT-treated patients and aspirin
alone. Treatment with extended DAPT had no significant effect
on non-CV death [RR 1.03 (95% CI 0.86–1.23); P ¼ 0.76; see Sup-
plementary material online, Figure S7]. The net effect was
a non-significant RR of 0.92 (95% CI 0.83–1.03; P ¼ 0.13; see
Supplementary material online, Figure S8) for all-cause mortality.
Sensitivity analyses
There was no meaningful heterogeneity in results across trials for
either the primary or the secondary endpoints. No evidence of pub-
lication bias was suggested by visual inspection of the funnel plots for
MACE (see Supplementary material online, Figure S9) or secondary
endpoints. Results for the primary endpoint analysis remained
significant after removal of any one trial from the pooled result
(see Supplementary material online, Table S5). More so, after simul-
taneous removal of both the PEGASUS-TIMI 54 and DAPT results,
the primary endpoint remained significant among the remaining four
trials [RR 0.82 (95% CI 0.70–0.97); P ¼ 0.02; ARD ¼ 1.11% (95% CI
0.09–2.13)]. The addition of 1-year landmark results from two trials
testing other strategies of more intensive antiplatelet therapy for
secondary prevention among stabilized patients .1 year from an
MI,30,31 also did not materially change the results [RR 0.79 (95%
CI 0.72–0.87); P, 0.00001; see Supplementary material online, Ap-
pendix Figure S10]. Finally, results did not significantly differ among
any subgroup for MACE or major bleeding (all P-interactions ≥0.09;
see Supplementary material online, Tables S6 and S7).
Figure 1 Risk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers re-
present risk ratios and horizontal lines the 95% confidence intervals with marker size reflecting the statistical weight of the study using inverse
variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% confidence intervals for major adverse
cardiovascular events. There was no significant between-trial heterogeneity (Q statistic ¼ 8.36, d.f. ¼ 5; P ¼ 0.14; I2 ¼ 40%).
Figure 2 Risk of individual cardiovascular and bleeding endpoints comparing extended dual antiplatelet therapy vs. aspirin alone. Square data
markers represent risk ratios and horizontal lines the 95% confidence intervals using inverse variance random effects meta-analysis.
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Discussion
Our meta-analysis of .33 000 high-risk patients stabilized following
an MI found that, overall compared with aspirin alone, extended
DAPT beyond 1 year resulted in a 22% relative and 1.1% absolute
risk reduction for major adverse cardiovascular events over a
mean 31 months of follow-up. The magnitude of this relative risk re-
duction was consistent, with no significant heterogeneity, or sensi-
tivity to removing any one trial from the pooled results. The pooled
data in our meta-analysis show for the first time that there is a sig-
nificant 15% reduction in cardiovascular death in post-MI patients
receiving long-term DAPT. There was a 0.8% absolute increase in
the risk of major bleeding, but without significant excess of ICH
or fatal bleeding and no impact on non-cardiovascular causes of
death.
This meta-analysis differs in important ways from prior re-
ports.32 – 36 We elected to focus on stabilized patients with a his-
tory of prior MI since these patients are known to be at higher
atherothrombotic risk compared with patients with SIHD treated
with elective PCI.9,24,37,38 As such, we reasoned that these patients
would be expected to demonstrate a more favourable
benefit-to-risk profile when treated with long-term DAPT com-
pared with patients without a prior MI. We also focused on trials
that randomized at least one arm of this population to a strategy
of DAPT .1 year following a qualifying MI vs. aspirin alone. We
did this in order to address the unresolved question of whether
treatment of patients with a history of MI with DAPT beyond the
currently recommended 1-year duration results in significant and
clinically meaningful reductions in atherothrombotic events. As
well, we leveraged the power of a larger population to better quan-
tify the magnitude of bleeding risk with this strategy and refine risk
estimates for cardiovascular and non-cardiovascular causes of
death. Finally, we analysed eligible trials irrespective of whether,
when, and how patients were treated with PCI, since data support
up to a year of DAPT post-MI regardless of whether patients
underwent PCI. Patients with MI treated with PCI have
stent-related factors that may modify the benefit–risk trade-off
of extended DAPT, including the timing and propensity for late
stent thrombosis39,40; however, the benefit of extended DAPT
was consistent regardless of whether trials exclusively enrolled pa-
tients undergoing PCI or not.
Our findings of reduced atherothrombotic risk with extended
DAPT irrespective of whether trials enrolled only PCI-treated pa-
tients support prior research that suggests the mechanism of long-
term cardiovascular benefit with extended DAPT in patients with a
history of prior MI is likely an extension of the benefits seen follow-
ing early treatment of an MI, and distinct from simply preventing
stent thrombosis in patients with prior PCI. For instance, long
term, the majority of ruptured coronary plaques that result in recur-
rent MI appear to occur in lesions other than earlier culprits treated
with PCI in patients with coronary heart disease.18,29,41 After an in-
farction, patients have a more susceptible coronary milieu and are
more prone to recurrent plaque rupture with prolonged platelet ac-
tivation and aggregation1 – 3,42 and higher circulating markers of
myonecrosis and inflammation43 compared with stable patients
which may mediate a preferential benefit from extended DAPT.
Furthermore, prolonged DAPT in patients with a history of prior
MI appeared to reduce ischaemic events in other arterial territories,
in accordance with our observed results for stroke.
Coronary heart disease treatment guidelines recommend 1 year
of DAPT in patients following MI, based simply on the original dur-
ation of pivotal secondary prevention RCTs,11 – 15 although land-
mark analyses from these trials suggested continued divergence of
event curves with time.44 – 46 This recommendation was extended
to patients treated with coronary revascularization by PCI,15,47
based on expert consensus and observational studies suggesting a
delayed propensity for complete endothelialization and subsequent
risk of late stent thrombosis following discontinuation of DAPT in
patients treated with early generation drug-eluting stents.48,49 Sub-
sequently, a number of small RCTs have randomized patients trea-
ted with PCI to shorter durations of DAPT and concluded that
1-year duration of DAPT may offer no benefit compared with short-
er courses of therapy.50 – 55 However, none of these prior trials
were powered to study this question, each enrolled limited numbers
of subjects with MI, and prior meta-analyses have not distinguished
treatment effects between acute and stable coronary patients.32 –36
To the best of our knowledge, there are at least eight ongoing out-
comes trials comparing experimental with traditional DAPT strat-
egies enrolling patients following PCI (see Supplementary material
online, Table S8). These trials will greatly inform the care of patients
receiving stents. However, each of these trials is primarily focused
on PCI, whereas our meta-analysis results pertain to the patient’s
underlying history of MI irrespective of PCI status.
Considering the inclusion and exclusion criteria of the trials we
studied certain characteristics that may define stabilized high-risk
patients with previous MI at low risk of bleeding that benefit from
extended DAPT. The majority of patients studied were considered
high risk for recurrent atherothrombotic events with 93% having a
history of biomarker positive acute coronary syndrome often in the
presence of additional risk factors such as older age, diabetes, or
established atherosclerosis. Studies typically excluded patients
with a bleeding diathesis such as a coagulation disorder or long-term
anticoagulation therapy, recent (within 6–12 months) or active
major bleeding such as gastrointestinal bleeding, recent (within
1 month) major surgery, or any history of ICH. In addition, very
few patients enrolled had a history of a prior stroke or TIA
(,3%). As such, our findings may not be generalizable to all acute
coronary syndrome patients,56 such as patients with unstable angina
or a history of stroke, but may be most accurately applied to patients
with a prior history of MI who have tolerated 1 year of DAPT
without development of, or ongoing risk for, significant bleeding.
There are certain limitations to this study. First, we pooled trials
with heterogeneous populations that varied in treatment strategy,
study design, intended primary outcome, and major bleeding defini-
tions. For logistical reasons, we did not evaluate individual patient-
level data, but unpublished data for several endpoints were provided
by individual PIs to compare standard endpoints among similar pa-
tients across trials. Second, some of the RCTs were unblinded,
which may bias reporting of non-fatal adverse cardiovascular and
bleeding events. However, these unblinded trials provided ,15%
of the total population studied and all trials utilized blinded central
committee endpoint adjudication. Third, five of the six included
trials focused on subgroups, as they were not prospectively de-
signed to determine whether extended DAPT was beneficial in
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post-MI patients. However, meta-analysis of randomized compari-
sons within each subgroup of patients with a history of MI remain
valid. Finally, although three-quarters of the primary outcome
events analysed were contributed from the PEGASUS-TIMI
54 and DAPT trials, our primary endpoint results were robust
and remained significant after removal of both trials from the pooled
result. Additionally, for the first time, pooling of these trials allowed
detection of a significant reduction in cardiovascular death.
In summary, compared with aspirin alone, extended DAPT
beyond 1 year among stabilized high-risk patients with previous
MI decreased the risk of MACE, including cardiovascular death
alone, as well as recurrent MI and stroke. There was an increase
in the risk of major bleeding, but not fatal bleeding, with no excess
of non-cardiovascular causes of death. These findings now clarify
that in patients with prior MI who are at low risk of bleeding, con-
tinuation of DAPT beyond a year offers a substantial reduction in
important cardiovascular outcomes and should be considered.
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